 |
 |
Amarin Corporation to Present at Friedland Capital's Biotech, Medical And Healthcare Conference Tuesday September 23, 9:01 am ET LONDON, Sept. 23 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN - News; "Amarin") announced today that it would participate in Friedland Capital's Biotech, Medical and Healthcare Conference. A presentation will be made by Rick Stewart, Chief Executive Officer on September 24, 2003 at 9.20 a.m. EDT at The Harvard Club of New York. This conference, including Amarin's presentation, will be simultaneously audio webcast "live" and after the conference the audio webcast will be archived at: http://www.friedlandcapitalevents.com/duttonwebcast.htm Amarin Corporation plc is a specialty pharmaceutical company focused on neurology. The Company plans to become a leader in these therapeutic categories by providing innovative products and solutions that address significant unmet medical needs. Amarin has eleven pharmaceutical products on the US market along with a development pipeline that includes two late-stage candidates: Zelapar(TM) (selegiline orally disintegrating tablets), for Parkinson's disease and LAX-101, a proprietary compound for Huntington's Disease. For press releases and other corporate information, visit our website at http://www.amarincorp.com Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties which may cause the Company's actual results in future periods to be materially different from any performance suggested herein. Such risks and uncertainties include, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development and commercialisation, the impact of competitive products and patents, as well as other risks and uncertainties detailed from time to time in periodic reports. For more information, please refer to Amarin Corporation's Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and Exchange Commission. The Company assumes no obligation to update information on its expectations. Source: Amarin Corporation plc SOURCE: PR Newswire / Yahoo News (press release) http://biz.yahoo.com/prnews/030923/lntu006_1.html * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn